X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
mepolizumab (681) 681
index medicus (458) 458
asthma (433) 433
humans (411) 411
immunology (252) 252
allergy (234) 234
respiratory system (193) 193
asthma - drug therapy (167) 167
double-blind (167) 167
inflammation (156) 156
eosinophils (139) 139
male (136) 136
female (135) 135
omalizumab (134) 134
exacerbations (133) 133
adult (126) 126
asthma - immunology (114) 114
abridged index medicus (102) 102
cytokines (101) 101
patients (99) 99
biomarkers (95) 95
middle aged (95) 95
anti-asthmatic agents - therapeutic use (94) 94
severe eosinophilic asthma (94) 94
animals (90) 90
monoclonal antibodies (89) 89
benralizumab (87) 87
il-5 (87) 87
leukocytes (87) 87
eosinophilic asthma (85) 85
safety (84) 84
severe asthma (82) 82
eosinophils - immunology (79) 79
allergy and immunology (78) 78
efficacy (78) 78
eosinophilia (77) 77
monoclonal-antibody (77) 77
persistent asthma (74) 74
antibodies, monoclonal - therapeutic use (72) 72
interleukin-5 (72) 72
severity of illness index (72) 72
antibodies, monoclonal, humanized - therapeutic use (71) 71
medicine, general & internal (71) 71
phenotypes (70) 70
reslizumab (70) 70
studies (69) 69
drug therapy (68) 68
eosinophil (67) 67
hypereosinophilic syndrome (67) 67
treatment outcome (67) 67
care and treatment (66) 66
corticosteroids (65) 65
asthma - physiopathology (63) 63
pharmacology & pharmacy (63) 63
placebo (63) 63
disease (61) 61
analysis (60) 60
allergies (59) 59
asthma - diagnosis (59) 59
clinical trials (59) 59
multicenter (59) 59
interleukin-5 - immunology (55) 55
phenotype (55) 55
adults (54) 54
inhaled corticosteroids (53) 53
medical research (53) 53
interleukin 5 (52) 52
therapy (52) 52
children (51) 51
interleukin-5 - antagonists & inhibitors (51) 51
leukocyte count (50) 50
sputum (50) 50
research (48) 48
mepolizumab therapy (47) 47
respiratory tract diseases (47) 47
airway inflammation (46) 46
cluster-analysis (46) 46
eosinophilic esophagitis (46) 46
quality of life (46) 46
adolescent (45) 45
aged (44) 44
article (44) 44
young adult (44) 44
asthma - pathology (43) 43
asthma - therapy (43) 43
critical care medicine (43) 43
eosinophils - pathology (43) 43
immunoglobulin e (43) 43
antibody (40) 40
disease progression (40) 40
interleukins (40) 40
child (39) 39
expression (39) 39
receptor (39) 39
biologics (38) 38
drug dosages (38) 38
medicine, research & experimental (38) 38
asthma - metabolism (37) 37
blood (36) 36
health aspects (36) 36
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (708) 708
German (22) 22
French (16) 16
Spanish (5) 5
Korean (2) 2
Russian (2) 2
Croatian (1) 1
Italian (1) 1
Japanese (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of allergy and clinical immunology, ISSN 0091-6749, 08/2019
Mepolizumab is approved for patients with severe asthma with an eosinophilic phenotype aged ≥12 (US) or ≥6 (EU) years, but its long-term use in children aged... 
Journal Article
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ISSN 0091-6749, 06/2015, Volume 135, Issue 6, pp. 1662 - 1663
Journal Article
Zeitschrift fur Rheumatologie, ISSN 0340-1855, 2019
Journal Article
Journal of Asthma, ISSN 0277-0903, 05/2019, Volume 56, Issue 5, pp. 473 - 474
A Combination of Mepolizumab and Omaluzimab injections for severe asthma. Introduction. Patients with severe persistent asthma account for a large proportion... 
severe asthma | omalizumab | mepolizumab | ALLERGY | RESPIRATORY SYSTEM
Journal Article
Clinical & Experimental Allergy, ISSN 0954-7894, 06/2019, Volume 49, Issue 6, pp. 929 - 931
Journal Article
LANCET RESPIRATORY MEDICINE, ISSN 2213-2600, 09/2016, Volume 4, Issue 9, pp. 699 - 707
Background Eosinophilic airway inflammation is often present in asthma, and reduction of such inflammation results in improved clinical outcomes. We... 
APOPTOSIS | TH2 CELLS | MEPOLIZUMAB | EFFICACY | CRTH2 ANTAGONIST | RESPIRATORY SYSTEM | EXACERBATIONS | VALIDATION | T(H)2 CELLS | QUESTIONNAIRE | OC000459 | CRITICAL CARE MEDICINE
Journal Article
Annals of Allergy, Asthma & Immunology, ISSN 1081-1206, 10/2019
Journal Article
INTERNIST, ISSN 0020-9554, 05/2018, Volume 59, Issue 5, pp. 497 - 504
Journal Article
Thorax, ISSN 0040-6376, 02/2015, Volume 70, Issue 2, pp. 115 - 120
Background Monitoring sputum eosinophils in asthma predicts exacerbations and improves management of asthma. Thus far, blood eosinophils and FENO show... 
NITRIC-OXIDE LEVELS | MEPOLIZUMAB | BIOMARKER | AIRWAY INFLAMMATION | PHENOTYPES | INTERLEUKIN-5 | Asthma | Eosinophil Biology | COUNTS | RESPIRATORY SYSTEM | EXACERBATIONS | PLACEBO-CONTROLLED TRIAL | CORTICOSTEROIDS | Care and treatment | Inflammation | Diagnosis | Health aspects | Eosinophils | Studies | Biomarkers | Population | Accuracy
Journal Article
NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 08/2017, Volume 377, Issue 6, pp. 597 - 598
Journal Article
The World Allergy Organization journal, ISSN 1939-4551, 08/2019, Volume 12, Issue 8, p. 100050
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex upper airway disease affecting up to 11% of the population of Western Europe. In these western... 
Journal Article
Revue des Maladies Respiratoires, ISSN 0761-8425, 02/2019, Volume 36, Issue 2, pp. 179 - 190
Introduction: This paper reports the French data from a post-hoc analysis of the international IDEAL study, which aimed to describe a recent cohort of patients... 
Observational study | Omalizumab | Severe asthma | Mepolizumab
Journal Article
The European respiratory journal, ISSN 0903-1936, 10/2018, Volume 52, Issue 4
This review provides an overview of the role of long-term treatment of severe asthma with oral corticosteroids (OCS) and its associated side-effects in adults.... 
OMALIZUMAB | MEPOLIZUMAB | RESPIRATORY SYSTEM | COMPLICATIONS | QUALITY-OF-LIFE | BURDEN | ADVERSE EVENTS
Journal Article
Clinical & Experimental Allergy, ISSN 0954-7894, 05/2012, Volume 42, Issue 5, pp. 712 - 737
Summary Interleukin‐5 is a Th2 homodimeric cytokine involved in the differentiation, maturation, migration, development, survival, trafficking and effector... 
reslizumab | mepolizumab | interleukin‐5 receptor | eosinophils | asthma | benralizumab | interleukin‐5 | Benralizumab | Interleukin-5 receptor | Mepolizumab | Interleukin-5 | Asthma | Eosinophils | Reslizumab | CHURG-STRAUSS-SYNDROME | ACTIVATED PROTEIN-KINASE | COLONY-STIMULATING FACTOR | COMMON BETA-SUBUNIT | RANDOMIZED CONTROLLED-TRIAL | IMMUNOLOGY | REFRACTORY EOSINOPHILIC ASTHMA | interleukin-5 | OBSTRUCTIVE PULMONARY-DISEASE | ALLERGY | ANTI-IL-5 MEPOLIZUMAB THERAPY | HUMANIZED MONOCLONAL-ANTIBODY | interleukin-5 receptor | RESPIRATORY SYNCYTIAL VIRUS | Signal Transduction | Interleukin-5 - metabolism | Humans | Antibodies, Monoclonal - adverse effects | Hypersensitivity - immunology | Antibodies, Monoclonal - therapeutic use | Eosinophils - immunology | Hypersensitivity - drug therapy | Anti-Allergic Agents - therapeutic use | Animals | Interleukin-5 - antagonists & inhibitors | Anti-Allergic Agents - adverse effects | Protein Binding | Receptors, Interleukin-5 - antagonists & inhibitors | Receptors, Interleukin-5 - metabolism | Disease Models, Animal | Cytokines | Medical research | Rodents | Corticoids | Animal models | Gastrointestinal tract diseases | Leukocyte migration | Helper cells | Cytotoxicity | Lymphocytes T | Blood | Churg-Strauss syndrome | Interleukin 5 | Atopic dermatitis | Interleukin 3 | Chronic obstructive pulmonary disease | Cell survival | Immune response | Granulocyte-macrophage colony-stimulating factor | Leukocytes (eosinophilic) | Antisense oligonucleotides | Inflammation | siRNA | Eosinophilia | Side effects | Reviews | Monoclonal antibodies | Interleukin 5 receptors | Mast cells | Differentiation | Leukocytes (basophilic) | polyposis
Journal Article
Journal Article
European Respiratory Journal, ISSN 0903-1936, 05/2017, Volume 49, Issue 5, pp. 1700634 - 1700634
Asthma is widely accepted as a complex heterogeneous condition with diverse pathophysiological mechanisms, clinical presentations, comorbidities, physiological... 
PLACEBO | MULTICENTER | MEPOLIZUMAB | RESPIRATORY SYSTEM | DREAM | DOUBLE-BLIND | RECEPTOR | MONOCLONAL-ANTIBODY | PHENOTYPES | BENRALIZUMAB | Leukocytes (eosinophilic) | Inflammation | Asthma
Journal Article
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, ISSN 1073-449X, 12/2013, Volume 188, Issue 12, pp. 1468 - 1469
Journal Article